Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hologic Expects 2010 Launch Of Tomosynthesis System After FDA Panel Delay

This article was originally published in The Gray Sheet

Executive Summary

Hologic is now forecasting a late 2010 launch of its Selenia Dimensions tomosynthesis three-dimensional mammography system, after recent discussions with FDA led the firm to back out of a planned June advisory panel review

You may also be interested in...



Hologic Selenia 3D Digital Mammography System Gets Panel Nod

FDA's Radiological Devices Advisory Panel unanimously endorsed safety and efficacy data on Hologic's Selenia Dimensions 3D three-dimensional digital mammography system for screening and diagnosis of breast cancer at a Sept. 24 meeting

Hologic Selenia 3D Digital Mammography System Gets Panel Nod

FDA's Radiological Devices Advisory Panel unanimously endorsed safety and efficacy data on Hologic's Selenia Dimensions 3D three-dimensional digital mammography system for screening and diagnosis of breast cancer at a Sept. 24 meeting

Hologic Sales Drop In Q1 Despite Signs Of Capital-Equipment Market Recovery

Women's health firm Hologic reported a 10% decline in its breast health unit quarterly sales compared to last year on Feb. 1, but a 2.5% sequential increase from the prior quarter, indicating that the market for large capital equipment may be stabilizing, the firm said

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT027422

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel